Back HCV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

Antiviral Therapy for Hepatitis C, Especially with Sustained Response, Lowers Liver Cancer Risk

Interferon-based antiviral therapy lowers the likelihood that people with liver fibrosis or cirrhosis due to chronic hepatitis C will develop hepatocellular carcinoma (HCC), with the greatest risk reduction seen among those who achieve virological response, according to a study described in the October 22, 2012, edition of open-access online journal BMJ Open. alt

Read more:

EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

Read more:

Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients

Bristol-Meyers Squibb's investigational anti-cancer drug brivanib did not improve overall survival of patients with hepatocellular carcinoma (HCC) who were unable to take or did not respond to sorafenib (Nexavar) in the Phase 3 BRISK-PS trial, the company recently reported. The drug is still being tested in other patients populations.

Read more:

Hepatitis B and C Are Major Causes of Liver Cancer in U.S.

Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major cause of hepatocellular carcinoma (HCC, a form of primary liver cancer) in the U.S., according to a study by researchers at the Mayo Clinic in Rochester, MN. A related analysis found that among immigrants from Somalia, hepatitis B and C were both significant causes of liver cancer.

Read more:

AASLD 2011: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer

A genetically engineered vaccinia poxvirus (JX-594) can rapidly destroy tumors and prolong survival of people with advanced hepatocellular carcinoma (HCC), according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.alt

Read more: